0
     

Report Added
Report already added
Myocarditis Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update

Myocarditis Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Myocarditis - Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update, provides an overview of the Myocarditis (Cardiovascular) pipeline landscape.

Myocarditis is inflammation of the heart muscle. Myocarditis is an uncommon disorder that is usually caused by viral, bacterial, or fungal infections that reach the heart. Symptoms include chest pain, rapid or abnormal heartbeat, shortness of breath, at rest or during physical activity, fluid retention with swelling of legs, ankles and feet and fatigue. Treatment includes antibiotics, anti-inflammatory medicines to reduce swelling and diuretics to remove excess water from the body.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Myocarditis - Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update, provides comprehensive information on the therapeutics under development for Myocarditis (Cardiovascular), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Myocarditis (Cardiovascular) pipeline guide also reviews of key players involved in therapeutic development for Myocarditis and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase I, Preclinical and Discovery stages are 1, 1, 3 and 2 respectively. Similarly, the Universities portfolio in Preclinical stages comprises 1 molecules, respectively.

Myocarditis (Cardiovascular) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

- The pipeline guide provides a snapshot of the global therapeutic landscape of Myocarditis (Cardiovascular).
- The pipeline guide reviews pipeline therapeutics for Myocarditis (Cardiovascular) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Myocarditis (Cardiovascular) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Myocarditis (Cardiovascular) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Myocarditis (Cardiovascular)

Reasons to Buy

- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Myocarditis (Cardiovascular).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Myocarditis (Cardiovascular) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Table of Contents

List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Myocarditis - Overview
Myocarditis - Therapeutics Development
Pipeline Overview
Pipeline by Companies
Pipeline by Universities/Institutes
Products under Development by Companies
Products under Development by Universities/Institutes
Myocarditis - Therapeutics Assessment
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Myocarditis - Companies Involved in Therapeutics Development
Cantargia AB
Cardiol Therapeutics Inc
Dynomics Inc
Evotec SE
Inflamma Therapeutics LLC
Swedish Orphan Biovitrum AB
Worg Pharmaceuticals Hangzhou Co Ltd
Myocarditis - Drug Profiles
anakinra - Drug Profile
Product Description
Mechanism Of Action
History of Events
ATX-MYO - Drug Profile
Product Description
Mechanism Of Action
History of Events
CAN-10 - Drug Profile
Product Description
Mechanism Of Action
History of Events
cannabidiol 1 - Drug Profile
Product Description
Mechanism Of Action
History of Events
coxsackievirus B (hexavalent) vaccine - Drug Profile
Product Description
Mechanism Of Action
DYN-502 - Drug Profile
Product Description
Mechanism Of Action
IFT-100 - Drug Profile
Product Description
Mechanism Of Action
Recombinant Peptides for Myocardial Infarction and Myocarditis - Drug Profile
Product Description
Mechanism Of Action
Myocarditis - Dormant Projects
Myocarditis - Product Development Milestones
Featured News & Press Releases
Dec 13, 2021: Cantargia reports positive results for CAN10 antibody in preclinical systemic sclerosis model
Nov 08, 2021: Cantargia reports progress in manufacturing process development and provides update on clinical trial preparations for CAN10
Oct 25, 2021: Cardiol Therapeutics receives Health Canada approval for phase II clinical trial of CardiolRx for acute myocarditis
Aug 24, 2021: Cardiol Therapeutics receives FDA clearance of investigational new drug (IND) application for phase II clinical trial of CardiolRx for acute myocarditis
May 10, 2021: Cantargia presents new preclinical data showing unique improvement of heart function in myocarditis using antibody CAN10
Apr 28, 2021: Cardiol Therapeutics announces first patient enrolled in LANCER, a Phase II/III outcomes trial in high-risk patients hospitalized with COVID-19
Apr 26, 2021: Cantargia presents new preclinical data on antibody CAN10 at IMMMUNOLOGY2021
Apr 12, 2021: Cardiol Therapeutics announces topline results from phase I single and multiple ascending dose clinical trial of CardiolRx
Mar 19, 2021: Cantargia reports positive preclinical safety and efficacy results in the CAN10 project
Dec 22, 2020: Cardiol Therapeutics announces completion of phase I clinical study of CardiolRx
Nov 27, 2020: BioInvent signs monoclonal antibody manufacturing deal with Cantargia
Aug 26, 2020: Cardiol Therapeutics initiates Health Canada approved Phase 1 clinical study of CardiolRx
Apr 07, 2020: Cantargia provides update on development project CAN10
Apr 05, 2020: Cardiol Therapeutics receives Health Canada approval for phase 1 study of its pharmaceutically produced cannabidiol (CBD) formulation
Apr 01, 2020: Cardiol Therapeutics announces study results confirm the cardioprotective role of its pharmaceutical cannabidiol formulation in a model of heart failure
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

List of Tables
Number of Products under Development for Myocarditis, 2022
Number of Products under Development by Companies, 2022
Number of Products under Development by Universities/Institutes, 2022
Products under Development by Companies, 2022
Products under Development by Universities/Institutes, 2022
Number of Products by Stage and Target, 2022
Number of Products by Stage and Mechanism of Action, 2022
Number of Products by Stage and Route of Administration, 2022
Number of Products by Stage and Molecule Type, 2022
Myocarditis - Pipeline by Cantargia AB, 2022
Myocarditis - Pipeline by Cardiol Therapeutics Inc, 2022
Myocarditis - Pipeline by Dynomics Inc, 2022
Myocarditis - Pipeline by Evotec SE, 2022
Myocarditis - Pipeline by Inflamma Therapeutics LLC, 2022
Myocarditis - Pipeline by Swedish Orphan Biovitrum AB, 2022
Myocarditis - Pipeline by Worg Pharmaceuticals Hangzhou Co Ltd, 2022
Myocarditis - Dormant Projects, 2022

List of Figures
Number of Products under Development for Myocarditis, 2022
Number of Products under Development by Companies, 2022
Number of Products by Targets, 2022
Number of Products by Stage and Targets, 2022
Number of Products by Mechanism of Actions, 2022
Number of Products by Stage and Mechanism of Actions, 2022
Number of Products by Routes of Administration, 2022
Number of Products by Stage and Routes of Administration, 2022
Number of Products by Molecule Types, 2022
Number of Products by Stage and Molecule Types, 2022

Report Title: Myocarditis Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update


Your Details
Valid Invalid number

SELECT A FORMAT

ADD TO CART BUY NOW

Related Report

Dental Consumables Market by Product (Dental Implants, Orthodontics, Periodontics, Endodontics, Bridges, Crowns, Dentures, Clear aligners, Disinfectants, Pastes, Cups, Brushes, Accessories), End user (Dental Clinics, Hospitals) - Global Forecast to 2027

Dental Consumables Market by Product (Dental Implants, Orthodontics, Periodontics, Endodontics, Bridges, Crowns, Dentures, Clear aligners, Disinfectants, Pastes, Cups, Brushes, Accessories), End user (Dental Clinics, Hospitals) - Global Forecast to 2027

2022 Vietnam Clinical Chemistry Analyzers and Reagent Market--Supplier Shares, Forecasts for 55 Tests, Opportunities--Growth Strategies, Volume and Sales Segment Forecasts, Latest Technologies and Instrumentation Pipeline

2022 Vietnam Clinical Chemistry Analyzers and Reagent Market--Supplier Shares, Forecasts for 55 Tests, Opportunities--Growth Strategies, Volume and Sales Segment Forecasts, Latest Technologies and Instrumentation Pipeline

2022 Venezuela Clinical Chemistry Analyzers and Reagent Market--Supplier Shares, Forecasts for 55 Tests, Opportunities--Growth Strategies, Volume and Sales Segment Forecasts, Latest Technologies and Instrumentation Pipeline

2022 Venezuela Clinical Chemistry Analyzers and Reagent Market--Supplier Shares, Forecasts for 55 Tests, Opportunities--Growth Strategies, Volume and Sales Segment Forecasts, Latest Technologies and Instrumentation Pipeline

2022 Uruguay Clinical Chemistry Analyzers and Reagent Market--Supplier Shares, Forecasts for 55 Tests, Opportunities--Growth Strategies, Volume and Sales Segment Forecasts, Latest Technologies and Instrumentation Pipeline

2022 Uruguay Clinical Chemistry Analyzers and Reagent Market--Supplier Shares, Forecasts for 55 Tests, Opportunities--Growth Strategies, Volume and Sales Segment Forecasts, Latest Technologies and Instrumentation Pipeline

2022 United Arab Emirates Clinical Chemistry Analyzers and Reagent Market--Supplier Shares, Forecasts for 55 Tests, Opportunities--Growth Strategies, Volume and Sales Segment Forecasts, Latest Technologies and Instrumentation Pipeline

2022 United Arab Emirates Clinical Chemistry Analyzers and Reagent Market--Supplier Shares, Forecasts for 55 Tests, Opportunities--Growth Strategies, Volume and Sales Segment Forecasts, Latest Technologies and Instrumentation Pipeline

2022 Ukraine Clinical Chemistry Analyzers and Reagent Market--Supplier Shares, Forecasts for 55 Tests, Opportunities--Growth Strategies, Volume and Sales Segment Forecasts, Latest Technologies and Instrumentation Pipeline

2022 Ukraine Clinical Chemistry Analyzers and Reagent Market--Supplier Shares, Forecasts for 55 Tests, Opportunities--Growth Strategies, Volume and Sales Segment Forecasts, Latest Technologies and Instrumentation Pipeline